Sign in

CIK 0001549595

  • Large accelerated filer

Nurix Therapeutics, Inc.

Sign in to watch
Ticker
NRIX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Nov 30
Incorporated
DE
Entity type
Operating
EIN
270838048
Phone
+1 415-660-5320
Business address
1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
Former names
Nurix, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$1,712,859
in 10 filings, $1.0M under 10b5-1 plans

Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 1 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2021-02-18 Beaurang Pierre Chief Business Officer Sale −6,400 $35.99 $230K 1,400
2021-02-18 Beaurang Pierre Chief Business Officer Sale −1,000 $36.92 $37K 400
2021-02-18 Beaurang Pierre Chief Business Officer Sale −400 $37.88 $15K 0
2021-02-18 Beaurang Pierre Chief Business Officer Exercise or conversion · Employee Stock Option (right to buy) −9,107 14,226
2021-02-18 Beaurang Pierre Chief Business Officer Exercise or conversion · Employee Stock Option (right to buy) −3,797 72,869
2021-02-18 Beaurang Pierre Chief Business Officer Exercise or conversion · Employee Stock Option (right to buy) −2,096 14,678
2021-02-11 van Houte Hans Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +40,000 40,000
2021-02-11 SANDS ARTHUR T President, CEO Grant or award · Employee Stock Option (right to buy) +150,000 150,000
2021-02-11 Ring Christine General Counsel Grant or award · Employee Stock Option (right to buy) +40,000 40,000
2021-02-11 Hansen Gwenn Chief Scientific Officer Grant or award · Employee Stock Option (right to buy) +60,000 60,000
2021-02-11 Beaurang Pierre Chief Business Officer Grant or award · Employee Stock Option (right to buy) +40,000 40,000
2021-02-04 Third Rock Ventures III, L.P. 10% owner Other disposition −914,216 4,508,333
2020-11-30 Hansen Gwenn Chief Scientific Officer Exercise or conversion +12,000 $0.84 $10K 12,000
2020-11-30 Hansen Gwenn Chief Scientific Officer Exercise or conversion · Employee Stock Option (right to buy) −12,000 31,333
2020-10-21 SANDS ARTHUR T President, CEO Grant or award · Stock Option (right to buy) +804,170 804,170
2020-07-28 Redmile Group, LLC 10% owner Conversion +1,176,470 1,176,470
2020-07-28 Redmile Group, LLC 10% owner Conversion · Series D Redeemable Convertible Preferred Stock −1,176,470 0
2020-07-28 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner Conversion +784,313 784,313
2020-07-28 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner Conversion · Series D Preferred Stock −784,313 0
2020-07-28 COLUMN GROUP L P 10% owner Conversion +600,000 683,333

Page 40 of 42 · 829 trades